YARW:NASDAQ, Yarrow Bioscience Inc Com Par $ New
YARW stock overview
Yarrow Bioscience Inc Com Par $ New (YARW:NASDAQ) closed at $18.31 on October 16, 2026,
down 8.45% on the day.
The stock trades 61.0% below its 52-week high of $46.95
and 14.1% above its 52-week low of $16.05.
Over the past year, it lost 35.9%.
Yarrow Bioscience Inc Com Par $ New is part of the Health Care sector.
Key figures
- Price
- $18.31
- Day change
- -8.45%
- Volume
- 60,926
- Average volume
- 91,411
- Market cap
- 170M+
- 52-week range
- $16.05 – $46.95
- 50-day average
- $30.39
- 200-day average
- $31.24
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -7.62% |
-40.12% |
-54.68% |
-42.15% |
-35.87% |
Price action over the past year
In 178 trading sessions since February 3, 2026, YARW closed higher on 90 days (51%).
Its best day was September 17, 2026 (+17.89%) and its worst was July 24, 2026 (-44.85%).
The stock moved 10% or more in a single session 7 times.
Recent signals
YARW news
-
Sep 14, 2026:
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters Option to Purchase Additional Shares
-
Sep 14, 2026:
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Sep 11, 2026:
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
-
Sep 10, 2026:
Yarrow Bioscience Announces Proposed Underwritten Public Offering
-
Aug 13, 2026:
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Jul 27, 2026:
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
-
Jul 23, 2026:
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
-
Jul 21, 2026:
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
About Yarrow Bioscience Inc Com Par $ New
Yarrow is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases.
Similar stocks
Find more stocks like YARW with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.